Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;11(3):650-661.
doi: 10.1002/acn3.51985. Epub 2024 Jan 12.

Adaptive behavior assessed by Vineland-3 as comprehensive outcome measure in vanishing white matter

Affiliations

Adaptive behavior assessed by Vineland-3 as comprehensive outcome measure in vanishing white matter

Daphne H Schoenmakers et al. Ann Clin Transl Neurol. 2024 Mar.

Abstract

Objectives: Investigate the results and usability of the Vineland-3 as an outcome measure in vanishing white matter patients.

Methods: A cross-sectional investigation of the Vineland-3 based on interviews with caregivers, the Health Utilities Index, and the modified Rankin Scale in 64 vanishing white matter patients.

Results: Adaptive behavior measured with the Vineland-3 is impaired in the vast majority of vanishing white matter patients and significantly impacts daily life. Typically, the daily living skills domain is most severely affected and the socialization domain is the least affected. Based on the metric properties and the clinical relevance, the standard scores for the daily living skills domain and Adaptive Behavior Composite have the best properties to be used as an outcome measure.

Interpretation: The Vineland-3 appears to be a useful outcome measure to explore and quantify complex cognitive, behavioral, and psychiatric impairments affecting daily functioning in vanishing white matter. Further research should address the longitudinal evaluation of this tool and its additional value to standard neuropsychological and clinical examination.

PubMed Disclaimer

Conflict of interest statement

MSvdK: consultant for Calico (VWM) and coinvestigator for Ionis (Alexander disease trial), without personal payment. She is on patent P112686US00 “therapeutic effects of Guanabenz treatment in vanishing white matter” and on patent P112686CA00 “the use of Guanabenz in the treatment of VWM,” both for the VU University Medical Center, Amsterdam, The Netherlands. She is the initiator and principal investigator of the Guanabenz trial (https://www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001438‐25/NL), with permission of the Dutch national ethics committee (CCMO, NL61627.000.18). NIW: advisor and/or coinvestigator for trials in metachromatic leukodystrophy, Pelizaeus‐Merzbacher disease, and other leukodystrophies (Shire/Takeda, Orchard, Ionis, PassageBio, VigilNeuro, Sana Biotechnology, Lilly), without personal payment. The other authors (DHS, DP, JB, MDS, IvB, and MMCV) have nothing to declare.

Figures

Figure 1
Figure 1
Scatter plot of current age by age at onset. Legend: Current age groups: Yellow dot, <6 years. Blue dot, 6–<18 years. Red dot, ≥18 years.
Figure 2
Figure 2
V‐scale scores of subdomains by disease duration. The R2 of the exponential regression lines are the following: receptive: 0.336, expressive: 0.220, written: 0.340, personal: 0.269, domestic: 0.530, community: 0.474, interpersonal relationships: 0.192, play and leisure: 0.168, and coping: 0.251. Legend: Current age groups: Yellow dot, <6 years. Blue dot, 6–<18 years. Red dot, ≥18 years.
Figure 3
Figure 3
Standard scores of ABC and domains by disease duration. Exponential regression lines are shown with an R2 of ABC: 0.487, communication: 0.436, daily living skills: 0.578, and socialization: 0.372. Legend: Current age groups: Yellow dot, <6 years. Blue dot, 6–<18 years. Red dot, ≥18 years.
Figure 4
Figure 4
The ABC is plotted versus the HUI generic score (A) and modified Rankin Scale (B). The quadratic regression line for the correlation with the HUI generic score is shown and has an R2 of 0.581. The levels of the modified Rankin Scale correspond to the following clinical status: 0, no symptoms at all; 1, no significant disability despite symptoms, able to carry out all usual duties and activities; 2, slight disability, unable to carry out all previous activities, but able to look after own affairs without assistance; 3, moderate disability, requiring some help, but able to walk without assistance; 4, moderately severe disability, unable to walk and attend to bodily needs without assistance; 5, severe disability, bedridden, incontinent, and requiring constant nursing care and attention; and 6, dead. Legend: Current age groups: Yellow dot, <6 years. Blue dot, 6–<18 years. Red dot, ≥18 years.

Similar articles

Cited by

References

    1. van der Knaap MS, Pronk JC, Scheper GC. Vanishing white matter disease. The Lancet Neurology. 2006;5(5):413‐423. - PubMed
    1. Hamilton EMC, van der Lei HDW, Vermeulen G, et al. Natural history of vanishing white matter. Ann Neurol. 2018;84(2):274‐288. - PMC - PubMed
    1. van der Knaap MS, Leegwater PA, Könst AA, et al. Mutations in each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter. Ann Neurol. 2002;51(2):264‐270. - PubMed
    1. Leegwater PA, Vermeulen G, Konst AA, et al. Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. Nat Genet. 2001;29(4):383‐388. - PubMed
    1. van der Knaap MS, Bonkowsky JL, Vanderver A, et al. Therapy trial design in vanishing white matter: an expert consortium opinion. Neurol Genet. 2022;8(2):e657. - PMC - PubMed

LinkOut - more resources